Currently, a series of HDAC inhibitors are being tested clinically to treat relapsing multiple myeloma and cutaneous and peripheral T‐cell lymphomas.[42] However, the response to HDAC inhibitors in solid tumor treatment has been disappointing. This evidence concerns the gene HDAC9 and AL amyloidosis.